Prognostic value of CD34 expression status in patients with myxofibrosarcomas and undifferentiated pleomorphic sarcomas

Abstract It is controversial whether patients with myxofibrosarcomas (MFSs) have better prognoses than those with undifferentiated pleomorphic sarcomas (UPSs). No useful prognostic factors have been established to date. We therefore aimed to evaluate the prognostic value of CD34 expression status in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yoshiya Sugiura, Rikuo Machinami, Seiichi Matsumoto, Hiroaki Kanda, Keisuke Ae, Yutaka Takazawa, Kengo Takeuchi
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/304e61aea03045d886ea85f967be7160
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:304e61aea03045d886ea85f967be7160
record_format	dspace
spelling	oai:doaj.org-article:304e61aea03045d886ea85f967be71602021-12-02T16:25:00ZPrognostic value of CD34 expression status in patients with myxofibrosarcomas and undifferentiated pleomorphic sarcomas10.1038/s41598-021-94834-w2045-2322https://doaj.org/article/304e61aea03045d886ea85f967be71602021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-94834-whttps://doaj.org/toc/2045-2322Abstract It is controversial whether patients with myxofibrosarcomas (MFSs) have better prognoses than those with undifferentiated pleomorphic sarcomas (UPSs). No useful prognostic factors have been established to date. We therefore aimed to evaluate the prognostic value of CD34 expression status in 192 patients with MFSs and UPSs. Using the log-rank test, we showed that patients with MFSs had a significantly better overall survival than did those with UPSs when defining the former as having a > 10% myxoid component (p = 0.03), but not when defining it as having a > 50% myxoid component (p = 0.1). Under the definition of MFSs as > 10% myxoid component, the log-rank test revealed that the diagnosis of the UPS and the CD34 loss (p < 0.001) were significant adverse predictors of overall survival. As per the Cox model, the CD34 loss remained an independent prognostic factor (hazard ratio = 3.327; 95% confidence interval 1.334–8.295), while the diagnosis of the UPS was a nonsignificant confounding factor (hazard ratio = 1.084; 95% confidence interval 0.679–1.727). In conclusion, CD34 expression status is a useful prognostic factor in patients with MFS and UPS, and it should be incorporated into grading systems that are used to predict outcomes.Yoshiya SugiuraRikuo MachinamiSeiichi MatsumotoHiroaki KandaKeisuke AeYutaka TakazawaKengo TakeuchiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yoshiya Sugiura Rikuo Machinami Seiichi Matsumoto Hiroaki Kanda Keisuke Ae Yutaka Takazawa Kengo Takeuchi Prognostic value of CD34 expression status in patients with myxofibrosarcomas and undifferentiated pleomorphic sarcomas
description	Abstract It is controversial whether patients with myxofibrosarcomas (MFSs) have better prognoses than those with undifferentiated pleomorphic sarcomas (UPSs). No useful prognostic factors have been established to date. We therefore aimed to evaluate the prognostic value of CD34 expression status in 192 patients with MFSs and UPSs. Using the log-rank test, we showed that patients with MFSs had a significantly better overall survival than did those with UPSs when defining the former as having a > 10% myxoid component (p = 0.03), but not when defining it as having a > 50% myxoid component (p = 0.1). Under the definition of MFSs as > 10% myxoid component, the log-rank test revealed that the diagnosis of the UPS and the CD34 loss (p < 0.001) were significant adverse predictors of overall survival. As per the Cox model, the CD34 loss remained an independent prognostic factor (hazard ratio = 3.327; 95% confidence interval 1.334–8.295), while the diagnosis of the UPS was a nonsignificant confounding factor (hazard ratio = 1.084; 95% confidence interval 0.679–1.727). In conclusion, CD34 expression status is a useful prognostic factor in patients with MFS and UPS, and it should be incorporated into grading systems that are used to predict outcomes.
format	article
author	Yoshiya Sugiura Rikuo Machinami Seiichi Matsumoto Hiroaki Kanda Keisuke Ae Yutaka Takazawa Kengo Takeuchi
author_facet	Yoshiya Sugiura Rikuo Machinami Seiichi Matsumoto Hiroaki Kanda Keisuke Ae Yutaka Takazawa Kengo Takeuchi
author_sort	Yoshiya Sugiura
title	Prognostic value of CD34 expression status in patients with myxofibrosarcomas and undifferentiated pleomorphic sarcomas
title_short	Prognostic value of CD34 expression status in patients with myxofibrosarcomas and undifferentiated pleomorphic sarcomas
title_full	Prognostic value of CD34 expression status in patients with myxofibrosarcomas and undifferentiated pleomorphic sarcomas
title_fullStr	Prognostic value of CD34 expression status in patients with myxofibrosarcomas and undifferentiated pleomorphic sarcomas
title_full_unstemmed	Prognostic value of CD34 expression status in patients with myxofibrosarcomas and undifferentiated pleomorphic sarcomas
title_sort	prognostic value of cd34 expression status in patients with myxofibrosarcomas and undifferentiated pleomorphic sarcomas
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/304e61aea03045d886ea85f967be7160
work_keys_str_mv	AT yoshiyasugiura prognosticvalueofcd34expressionstatusinpatientswithmyxofibrosarcomasandundifferentiatedpleomorphicsarcomas AT rikuomachinami prognosticvalueofcd34expressionstatusinpatientswithmyxofibrosarcomasandundifferentiatedpleomorphicsarcomas AT seiichimatsumoto prognosticvalueofcd34expressionstatusinpatientswithmyxofibrosarcomasandundifferentiatedpleomorphicsarcomas AT hiroakikanda prognosticvalueofcd34expressionstatusinpatientswithmyxofibrosarcomasandundifferentiatedpleomorphicsarcomas AT keisukeae prognosticvalueofcd34expressionstatusinpatientswithmyxofibrosarcomasandundifferentiatedpleomorphicsarcomas AT yutakatakazawa prognosticvalueofcd34expressionstatusinpatientswithmyxofibrosarcomasandundifferentiatedpleomorphicsarcomas AT kengotakeuchi prognosticvalueofcd34expressionstatusinpatientswithmyxofibrosarcomasandundifferentiatedpleomorphicsarcomas
_version_	1718384042715381760

Prognostic value of CD34 expression status in patients with myxofibrosarcomas and undifferentiated pleomorphic sarcomas

Ejemplares similares